SCHEMBL422666

SCHEMBL422666

NC(=O)CN1CCNCC1

nearest known ligand 0.64

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.56
CHRM5 P08912 2/20 0.50
CHRM3 P20309 2/20 0.50
SIGMAR1 Q99720 6/20 0.46
TSHR P16473 2/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
CA2 P00918 2/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA9 Q16790 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CHKA P35790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13833227 1.00 KDM4E (0.56) KDM4ECHRM5CHRM3SIGMAR1TSHR
Hydrochloric Acid SCHEMBL4681 0.98 KDM4E (0.54) KDM4ECHRM5CHRM3SIGMAR1TSHR
Piperazine SCHEMBL28219481 0.98 KDM4E (0.54) KDM4ECHRM5CHRM3SIGMAR1TSHR
Hydrochloric Acid SCHEMBL1546636 0.98 KDM4E (0.54) KDM4ECHRM5CHRM3SIGMAR1TSHR
SCHEMBL10615036 0.98 KDM4E (0.54) KDM4ECHRM5CHRM3SIGMAR1TSHR
SCHEMBL23014609 0.98 KDM4E (0.54) KDM4ECHRM5CHRM3SIGMAR1TSHR
SCHEMBL3832605 0.98 KDM4E (0.54) KDM4ECHRM5CHRM3SIGMAR1TSHR
SCHEMBL22266260 0.92 KDM4E (0.53) KDM4ECHRM5CHRM3SIGMAR1TSHR
SCHEMBL1555048 0.92 SIGMAR1 (0.49) KDM4ECHRM5CHRM3SIGMAR1TSHR
SCHEMBL15043632 0.90 SIGMAR1 (0.48) KDM4ECHRM5CHRM3SIGMAR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 715 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122005693-A Application of Jiaweidanzhi Xiaoyao powder or extract thereof in preparation of medicines for treating depression complicated with ulcerative colitis 河南中医药大学 2026-05-12 CN claimed
US-20250353862-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-11-20 US claimed
EP-4301736-B1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2025-10-08 EP claimed
EP-4547671-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2025-05-07 EP claimed
CN-119255997-A Modulators of c-MYC mRNA translation and their use in the treatment of cancer 艾尼莫生物科技公司 2025-01-03 CN claimed
EP-4416268-A1 METHODS FOR PRODUCING CARTILAGE AND BONES Murdoch Children's Research Institute (AU) 2024-08-21 EP claimed
EP-4405343-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-07-31 EP claimed
CN-118307525-A Iridoid compound, preparation method thereof, pharmaceutical composition and application thereof 安徽中医药大学 2024-07-09 CN claimed
CN-118201915-A Pyridazinylamino derivatives as ALK5 inhibitors 奇斯药制品公司 2024-06-14 CN claimed
WO-2024010761-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2024-01-11 WO claimed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO claimed
WO-2007017577-A1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2007-02-15 WO claimed
US-20060287317-A1 SPHINGOSINE KINASE INHIBITORS APOGEE BIOTECHNOLOGY CORPORATION (US) 2006-12-21 US claimed
US-7135480-B2 Anticarcinogenic agents; colon, lymphoma, lung, prostate and breast cancers CYTOVIA, INC. (US) 2006-11-14 US claimed
EP-1578424-A2 SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A] QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS Cytovia, Inc. (US) 2005-09-28 EP claimed
US-20050014759-A1 Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2005-01-20 US claimed
WO-2004055163-A2 SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO[1,2-A]QUINOLINES CYTOVIA, INC. (US) 2004-07-01 WO claimed
EP-0862566-A1 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1998-09-09 EP claimed
WO-1997016440-A1 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1997-05-09 WO claimed
US-4610984-A CEREBRAL INSUFFICIENCY CASSELLA AKTIENGESELLSCHAFT (DE) 1986-09-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287317-A1 SPHINGOSINE KINASE INHIBITORS SPHK1, SPHK2, S1PR1 KDM4E 2438/4885CHRM5 4267/4885CHRM3 4072/4885
US-20250353862-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 KDM4E 1350/4885CHRM5 4849/4885CHRM3 4875/4885
US-20050014759-A1 Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis CASP3, CASP7, CASP1 KDM4E 570/4885CHRM5 4302/4885CHRM3 4542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.